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Introduction
Cognitive impairment is a common systemic manifestation of chronic obstructive pulmonary
disease (COPD) and is associated with higher levels of functional dependence [1], poorer
medical adherence [2] and greater mortality [3]. However, its neurobiological causes remain
unclear. We have previously reported greater volumes of hyperintense white matter lesions
(WML) and widespread white matter (WM) tissue microstructural changes (from Diffusion
Tensor Imaging, DTI) in people with COPD [4]. These and findings from other studies, such as
hypoperfusion [5][6], hippocampal atrophy [7], localised grey matter (GM) loss [8][9], and
presence of cerebral microbleeds [10] are consistent with a vascular pathophysiology.
However, several studies, including our own, are confounded by large group differences in
smoking history. The Novel Vascular Manifestations of COPD (NoVasC) study was designed to
address this limitation through direct comparison of COPD patients and smoking controls.
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Discussion
• COPD patients showed evidence of cerebral atrophy – significant reductions in
normalised whole-brain volume.
• Voxel-wise GM density and cortical thickness analyses did not identify any specific focus
for this GM loss, instead suggesting a cumulative effect of subtle generalised GM
reduction across the brain.
• These results are broadly consistent with previous reports of reduced GM density [8][9],
cortical thickness [12], and hippocampal volume [7] in COPD. However, these studies
found specific foci of change that were not replicated in this study.
• The present study found no evidence for greater WM atrophy, severity of WMLs,
microstructural tissue damage, disruption of WM connectivity, or hypoperfusion in
COPD patients when compared to smoking controls.
• This conflicts with previous reports of greater WM damage [4] and perfusion
abnormalities [5][6] in COPD. However, these previous findings were obtained through
comparison of COPD patients with healthy controls without statistical correction for
smoking history. Consequently, they may be indicative of a smoking-related effect.
However, this does not account for the cerebral atrophy observed in the present study.
Methods
Funding: British Lung Foundation Research Grant
Subjects: 27 COPD patients (age 67±8, 41% male, pack years 39±21, FEV1 58±18% predicted),
23 controls (age 63±9, 48% male, pack years 30±14, FEV1 101±19% predicted).
Key clinical measures: standard pulmonary function and spirometry testing (inc. blood
pressure), Montreal Cognitive Assessment (MoCA) (cognitive screen for dementia and mild
cognitive impairment), Hospital anxiety and depression scale (HADs).
MR Image acquisition: 3-Tesla T1-weighted (T1W) and Fluid-attenuated Inversion Recovery
(FLAIR) (tissue structure) , pseudo-Continuous Arterial Spin Labelling (pCASL) (cerebral blood
flow), Diffusion Tensor Imaging (DTI) (tissue microstructure).
Image analysis
Whole-brain
• T1W data were segmented into GM, WM and cerebrospinal (CSF) tissues-types [11].
• Tissue volumes were calculated and subsequently normalised with respect to total
intracranial volume (TIV=GM+WM+CSF).
• Image intensities on FLAIR (hyper-intense) and T1W (hypo/iso-intense) images were used
to delineate WMLs. Their number, average size and total normalised volume, were
calculated.
• Cortical thickness was computed from T1W tissue segmentation maps.
• Fractional Anisotropy (FA) and Mean Diffusivity (MD) maps calculated from DTI data,
provided measurement of tissue microstructure in the GM and WM.
• Cerebral Blood Flow (CBF) was calculated from the pCASL data and CBF values classified as
either GM or WM (using a Bayesian Markov Random Field model).
• Histogram parameters (mean, median, standard deviation, interquartile range, normalised
peak height , normalised peak values, skew, kurtosis) were used to describe the
distribution of cortical thickness, CBF, FA and MD values within each tissue-type (Fig. 1).
Local (voxel-wise)
• Voxel-based analysis of the GM, cortical thickness, WML and CBF maps, and tract-based
spatial statistics of the FA and MD maps, was performed.
WM connectivity (networks)
• WM connectivity was modelled as a network ‘wiring-diagram’, with WM fibres (traced from
the DTI using deterministic tractography) forming the connections (edges) and anatomical
cortical and deep-GM regions, the network nodes.
• ‘Graph’ metrics were used to describe the topological organisation of these networks in
terms of their connection density, the ‘quality’ of connections, the importance of particular
nodes, and the efficiency of communication both locally and between distributed areas.
Statistical analysis
• For continuous data, group differences were tested using parametric (Gaussian) and non-
parametric (non-Gaussian) variants of the general linear model (GLM). For the categorical voxel-
wise WML data Liebermeister tests were used.
• All GLM models controlled for the confounding effects of age and gender, with education
additionally included in cognitive analyses and TIV, in voxel-wise GM and cortical thickness
analyses.
• Additional models were tested controlling for vascular risk factors (pack years and mean arterial
pressure), and anxiety/depression (HADs).
• All voxel-wise analyses were corrected for multiplicity.
Results
Cognition: neither group met the criteria for dementia. There was a trend toward COPD having lower
cognitive function (p=0.069) but this was removed following correction for HADs score.
Whole-brain and network: COPD had significantly lower normalised GM volume (Table 1), which
survived correction for pack years, HADs score and mean arterial pressure. There were no other
significant differences in whole-brain volume, histogram or network measures.
Table 1: Whole-brain measures Controls (N=23) Patients (N=27) Difference
Mean
(Median)
SD (IQR) Mean
(Median)
SD (IQR) F P
Grey Matter Volume (% TIV) 42.96 1.43 41.71 1.46 6.91 0.01*
White Matter Volume (% TIV) 28.21 2.57 27.98 2.11 0.22 0.64
Tissue Volume Ratio 0.71 0.03 0.70 0.03 1.44 0.24
WML Volume (% TIV) (0.21) (0.27) (0.24) (0.35) 0.031 0.861
WML Number (27) (20) (23) (27) 0.011 0.991
WML Average Size (mm3) (94) (103) (126) (165) 0.041 0.851
Voxel-wise: neither the GM nor the cortical thickness maps showed significant foci of GM loss,
instead there was a pattern of generalised sub-significant reduction in GM across the whole brain
(Fig. 2). There were no localised difference in WML frequency (Fig. 3), CBF (Fig. 2) or tract-based FA
and MD values.
Figure 3: Group average WML maps
Figure 2: Voxel-wise GM maps
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Figure 1: Group histograms of whole-brain measures
N
or
m
al
is
ed
Fr
eq
ue
nc
y
(%
)
1Permutation general linear models (10000 perms.)
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